Mitochondrial dysfunction is considered to be one of the important pathogenesis in Parkinson’s disease (PD). We previously showed that pyrroloquinoline quinone (PQQ) could protect SH-SY5Y cells and dopaminergic neurons from cytotoxicity and prevent mitochondrial dysfunction in rotenone-induced PD models. In the present study we investigated the mechanisms underlying the protective effects of PQQ in a mouse PD model, which was established by intraperitoneal injection of rotenone (3 mg·kg−1·d−1, ip) for 3 weeks. Meanwhile the mice were treated with PQQ (0.8, 4, 20 mg·kg−1·d−1, ip) right after rotenone injection for 3 weeks. We showed that PQQ treatment dose-dependently alleviated the locomotor deficits and nigral dopaminergic neuron loss in PD mice. Furthermore, PQQ treatment significantly diminished the reduction of mitochondria number and their pathological change in the midbrain. PQQ dose-dependently blocked rotenone-caused reduction in the expression of PGC-1α and TFAM, two key activators of mitochondrial gene transcription, in the midbrain. In rotenone-injured human neuroblastoma SH-SY5Y cells, PTMScan Direct analysis revealed that treatment with PQQ (100 μM) differentially regulated protein phosphorylation; the differentially expressed phosphorylated proteins included the signaling pathways related with adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) pathway. We conducted Western blot analysis and confirmed that AMPK was activated by PQQ both in PD mice and in rotenone-injured SH-SY5Y cells. Pretreatment with AMPK inhibitor dorsomorphin (4 μM) significantly attenuated the protective effect and mitochondrial biogenesis by PQQ treatment in rotenone-injured SH-SY5Y cells. Taken together, PQQ promotes mitochondrial biogenesis in rotenone-injured mice and SH-SY5Y cells via activation of AMPK signaling pathway.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Raza C, Anjum R, Shakeel NUA. Parkinson’s disease: mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:17013.
Tang BL. Sirt1 and the mitochondria. Mol Cells. 2016;39:87–95.
Fernandez-Moriano C, Gonzalez-Burgos E, Gomez-Serranillos MP. Mitochondria-targeted protective compounds in Parkinson’s and Alzheimer’s diseases. Oxid Med Cell Longev. 2015;2015:408927.
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 2009;34:279–90.
Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology. 2015;46:101–16.
Tabata Y, Imaizumi Y, Sugawara M, Andoh-Noda T, Banno S, Chai M, et al. T-type calcium channels determine the vulnerability of dopaminergic neurons to mitochondrial stress in familial Parkinson disease. Stem Cell Rep. 2018;11:1171–84.
Lu J, Chen S, Shen M, He Q, Zhang Y, Shi Y, et al. Mitochondrial regulation by pyrroloquinoline quinone prevents rotenone-induced neurotoxicity in Parkinson’s disease models. Neurosci Lett. 2018;687:104–10.
Zhang ZN, Zhang JS, Xiang J, Yu ZH, Zhang W, Cai M, et al. Subcutaneous rotenone rat model of Parkinson’s disease: dose exploration study. Brain Res. 2017;1655:104–13.
Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018;18:21.
Zhang Q, Chen S, Yu S, Qin J, Zhang J, Cheng Q, et al. Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson’s disease. Neuropharmacology. 2016;108:238–51.
Zhang Q, Zhang J, Jiang C, Qin J, Ke K, Ding F. Involvement of ERK1/2 pathway in neuroprotective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury. Neuroscience. 2014;270:183–91.
Qin J, Wu M, Yu S, Gao X, Zhang J, Dong X, et al. Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson’s disease. Toxicol Lett. 2015;238:70–82.
Pajarillo E, Rizor A, Lee J, Aschner M, Lee E. The role of posttranslational modifications of alpha-synuclein and LRRK2 in Parkinson’s disease: potential contributions of environmental factors. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1992–2000.
Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M. Neuroprotective effect of the LRRK2 kinase inhibitor PF-06447475 in human nerve-like differentiated cells exposed to oxidative stress stimuli: implications for Parkinson’s disease. Neurochem Res. 2016;41:2675–92.
Zhang L, Hao J, Zheng Y, Su R, Liao Y, Gong X, et al. Fucoidan protects dopaminergic neurons by enhancing the mitochondrial function in a rotenone-induced rat model of Parkinson’s disease. Aging Dis. 2018;9:590–604.
Liu K, Xu H, Xiang H, Sun P, Xie J. Protective effects of Ndfip1 on MPP+-induced apoptosis in MES23.5 cells and its underlying mechanisms. Exp Neurol. 2015;273:215–24.
Stokes MP, Farnsworth CL, Moritz A, Silva JC, Jia X, Lee KA, et al. PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. Mol Cell Proteom. 2012;11:187–201.
Stokes MP, Silva JC, Jia X, Lee KA, Polakiewicz RD, Comb MJ. Quantitative profiling of DNA damage and apoptotic pathways in UV damaged cells using PTMScan Direct. Int J Mol Sci. 2012;14:286–307.
Choi DY, Lee MK, Hong JT. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol Dis. 2013;49:159–68.
Wang ES, Zhang XP, Yao HB, Wang G, Chen SW, Gao WW, et al. Tetranectin knockout mice develop features of Parkinson disease. Cell Physiol Biochem. 2014;34:277–87.
Calabresi P, Di Filippo M. Multitarget disease-modifying therapy in Parkinson’s disease? Lancet Neurol. 2015;14:975–6.
Felton LM, Anthony C. Biochemistry: role of PQQ as a mammalian enzyme cofactor? Nature. 2005;433:E10. discussion E11-2.
Misra HS, Rajpurohit YS, Khairnar NP. Pyrroloquinoline-quinone and its versatile roles in biological processes. J Biosci. 2012;37:313–25.
Wen H, He Y, Zhang K, Yang X, Hao D, He B. Mini-review: Functions and action mechanisms of PQQ in osteoporosis and neuro injury. Curr Stem Cell Res Ther. 2020;15:32–6.
Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010;285:142–52.
Jiang C, Jiang L, Li Q, Liu X, Zhang T, Yang G, et al. Pyrroloquinoline quinine ameliorates doxorubicin-induced autophagy-dependent apoptosis via lysosomal-mitochondrial axis in vascular endothelial cells. Toxicology. 2019;425:152238.
Wang Z, Li Y, Wang Y, Zhao K, Chi Y, Wang B. Pyrroloquinoline quinine protects HK-2cells against high glucose-induced oxidative stress and apoptosis through Sirt3 and PI3K/Akt/FoxO3a signaling pathway. Biochem Biophys Res Commun. 2019;508:398–404.
Zhang Y, Guo H, Guo X, Ge D, Shi Y, Lu X, et al. Involvement of Akt/mTOR in the neurotoxicity of rotenone-induced Parkinson’s disease models. Int J Environ Res Public Health. 2019;16:3811.
Valdez LB, Zaobornyj T, Bandez MJ, Lopez-Cepero JM, Boveris A, Navarro A. Complex I syndrome in striatum and frontal cortex in a rat model of Parkinson disease. Free Radic Biol Med. 2019;135:274–82.
Jiang X, Jin T, Zhang H, Miao J, Zhao X, Su Y, et al. Current progress of mitochondrial quality control pathways underlying the pathogenesis of Parkinson’s disease. Oxid Med Cell Longev. 2019;2019:4578462.
Gureev AP, Shaforostova EA, Popov VN. Regulation of mitochondrial biogenesis as a way for active longevity: interaction between the Nrf2 and PGC-1alpha signaling pathways. Front Genet. 2019;10:435.
Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813:1269–78.
Hwang P, Willoughby DS. Mechanisms behind pyrroloquinoline quinone supplementation on skeletal muscle mitochondrial biogenesis: possible synergistic effects with exercise. J Am Coll Nutr. 2018;37:738–48.
Zhang Q, Ding M, Cao Z, Zhang J, Ding F, Ke K. Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity. Neurochem Res. 2013;38:1661–71.
Diaz F, Moraes CT. Mitochondrial biogenesis and turnover. Cell Calcium. 2008;44:24–35.
Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism–emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012;125(Pt 21):4963–71.
Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. J Neurosci Res. 2017;95:2025–9.
Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res. 2008;79:208–17.
Kang I, Chu CT, Kaufman BA. The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms. FEBS Lett. 2018;592:793–811.
Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2:52ra73.
Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, et al. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci. 2012;69:1153–65.
Ng CH, Basil AH, Hang L, Tan R, Goh KL, O’Neill S, et al. Genetic or pharmacological activation of the Drosophila PGC-1alpha ortholog spargel rescues the disease phenotypes of genetic models of Parkinson’s disease. Neurobiol Aging. 2017;55:33–7.
Hasegawa K, Yasuda T, Shiraishi C, Fujiwara K, Przedborski S, Mochizuki H, et al. Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults. Nat Commun. 2016;7:10943.
Kato C, Kawai E, Shimizu N, Mikekado T, Kimura F, Miyazawa T, et al. Determination of pyrroloquinoline quinone by enzymatic and LC-MS/MS methods to clarify its levels in foods. PLoS One. 2018;13:e0209700.
Wang Y, Liu J, Chen M, Du T, Duan C, Gao G, et al. The novel mechanism of rotenone-induced alpha-synuclein phosphorylation via reduced protein phosphatase 2A activity. Int J Biochem Cell Biol. 2016;75:34–44.
Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48:e245.
Wu SB, Wu YT, Wu TP, Wei YH. Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochim Biophys Acta. 2014;1840:1331–44.
Zhang M, Deng YN, Zhang JY, Liu J, Li YB, Su H, et al. SIRT3 protects rotenone-induced injury in SH-SY5Y cells by promoting autophagy through the LKB1-AMPK-mTOR pathway. Aging Dis. 2018;9:273–86.
Ramalingam M, Huh YJ, Lee YI. The impairments of alpha-synuclein and mechanistic target of rapamycin in rotenone-induced SH-SY5Y cells and mice model of Parkinson’s disease. Front Neurosci. 2019;13:1028.
Marin TL, Gongol B, Zhang F, Martin M, Johnson DA, Xiao H, et al. AMPK promotes mitochondrial biogenesis and function by phosphorylating the epigenetic factors DNMT1, RBBP7, and HAT1. Sci Signal. 2017;10:eaaf7478.
Chaube B, Malvi P, Singh SV, Mohammad N, Viollet B, Bhat MK. AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1alpha-mediated mitochondrial biogenesis. Cell Death Disco. 2015;1:15063.
Irrcher I, Ljubicic V, Kirwan AF, Hood DA. AMP-activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS One. 2008;3:e3614.
Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A. 2007;104:12017–22.
Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, et al. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy. 2011;7:40–50.
Moon JH, Jeong JK, Hong JM, Seol JW, Park SY. Inhibition of autophagy by captopril attenuates prion peptide-mediated neuronal apoptosis via AMPK activation. Mol Neurobiol. 2019;56:4192–202.
Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, Codogno P, et al. AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem. 2006;281:34870–9.
Filomeni G, Graziani I, De Zio D, Dini L, Centonze D, Rotilio G, et al. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson’s disease. Neurobiol Aging. 2012;33:767–85.
This study was supported by the National Key Research and Development Program of China (Grant No. 2017YFA0104700), National Natural Science Foundation of China (81771404), the Natural Science Foundation of Jiangsu Province (Grant No. BK20161285), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Provincial Key Medical Center, and Jiangsu Students’ innovation and entrepreneurship training program (Grant No. 201810304096X).
The authors declare no competing interests.
About this article
Cite this article
Cheng, Q., Chen, J., Guo, H. et al. Pyrroloquinoline quinone promotes mitochondrial biogenesis in rotenone-induced Parkinson’s disease model via AMPK activation. Acta Pharmacol Sin 42, 665–678 (2021). https://doi.org/10.1038/s41401-020-0487-2
- Parkinson’s disease
- pyrroloquinoline quinone
- mitochondrial biogenesis
- PTMScan Direct analysis
Chemical Research in Toxicology (2021)
Ghrelin protects against rotenone-induced cytotoxicity: Involvement of mitophagy and the AMPK/SIRT1/PGC1α pathway